Shanghai BCI maker whose semi-invasive NEO implant (with Tsinghua) won the world's first commercial approval for an invasive-class BCI (NMPA, 2026).
Neuracle performed the world's first surgical implant of a commercially approved BCI at a Shanghai hospital on July 13. The coin-sized NEO device — cleared by China's NMPA in March — sits on the sensorimotor cortex of a patient who lost hand function in a car crash a decade ago, translating neural signals into movement via a robotic glove.
Neuracle (Shanghai) — Neuracle's NMPA-approved NEO implant was surgically placed in a paying patient at a Shanghai hospital — a man who lost hand function in a car crash a decade ago — the first time a commercially approved BCI has been implanted anywhere, four months after clearance and ahead of Neuralink.
Neuracle / NMPA (China) — China's NMPA cleared Neuracle's coin-sized NEO implant (developed with Tsinghua) for commercial sale to restore hand function after spinal-cord injury — the first invasive-class BCI approved for market anywhere, ahead of Neuralink.
No coverage matches this filter yet.